Medicare (CMS) August 19th 2018 Local Coverage Determination (LCD) Updates

Centers for Medicare & Medicaid Services (CMS) Local Coverage Determination (LCD) Updates »

August 19th Medicare (CMS) 2018 LCD Updates:

• A55315             Billing and Coding for Proton Beam Therapy
• A55709             Coenzyme Q10 (Q10) Coding and Billing Guideline
• L34416 (retired) Computerized Axial Tomography of the Chest/Thorax
• A56108             Destruction of internal hemorrhoid(s) by infrared coagulation (IRC) retired Part A and Part B LCD
• L37628              In Vitro Chemosensitivity & Chemoresistance Assays
• L37630              In Vitro Chemosensitivity & Chemoresistance Assays
• A56071             In Vitro Chemosensitivity Assays-Billing and Coding Guidelines
• A56073             In Vitro Chemosensitivity Assays-Billing and Coding Guidelines
• L37779              Intraoperative Radiation Therapy
• A54989 (retired)        MolDX: Billing and Coding for Lynch Syndrome Testing Services
• L36129              MolDX: Biomarkers in Cardiovascular Risk Assessment
• L36082              MolDX: BRCA1 and BRCA2 Genetic Testing
• L36425              MolDX: Breast Cancer Assay: Prosigna
• L35631              MolDX: Breast Cancer Index℠ Genetic Assay
• L35332              MolDX: CYP2C19, CYP2D6, CYP2C9, and VKORC1 Genetic Testing
• L37295              MolDX: EndoPredict® Breast Cancer Gene Expression Test
• L37311              MolDX: EndoPredict® Breast Cancer Gene Expression Test
• L35349              MolDX: Genetic Testing for Lynch Syndrome
• A56103             MolDX: Microsatellite Instability-High (MSI-H) and Mismatch Repair Deficient (dMMR) Biomarker Billing and Coding Guidelines for Patients with Unresectable or Metastatic Solid Tumors
• A56104             MolDX: Microsatellite Instability-High (MSI-H) and Mismatch Repair Deficient (dMMR) Biomarker Billing and Coding Guidelines for Patients with Unresectable or Metastatic Solid Tumors
• A56106             MolDX: Microsatellite Instability-High (MSI-H) and Mismatch Repair Deficient (dMMR) Biomarker Coding and Billing Guidelines for Patients with Unresectable or Metastatic Solid Tumors
• L37305              MolDX: Oncotype DX® Genomic Prostate Score for Men with Favorable Intermediate Risk Prostate Cancer
• L37321              MolDX: Oncotype DX® Genomic Prostate Score for Men with Favorable Intermediate Risk Prostate Cancer
• L37080              MolDX: Prolaris™ Prostate Cancer Genomic Assay for Men with Favorable Intermediate Risk Disease
• L37082              MolDX: Prolaris™ Prostate Cancer Genomic Assay for Men with Favorable Intermediate Risk Disease
• L36665              MolDX: ProMark Risk Score
• L37352              MolDX: Prometheus IBD sgi Diagnostic Policy
• L36006              MolDX-CDD: ConfirmMDx Epigenetic Molecular Assay
• L35175              MRI and CT Scans of the Head and Neck
• L37373              MRI and CT Scans of the Head and Neck
• L36658              Proton Beam Therapy
• A56076             Response to Comments: In Vitro Chemosensitivity & Chemoresistance Assays
• A56077             Response to Comments: In Vitro Chemosensitivity & Chemoresistance Assays
• A56105             Response to Comments: MolDX: ProMark Risk Score
• A56061             Response to Comments: MRI and CT Scans of Head and Neck
• A56067             Response to Comments: MRI and CT Scans of Head and Neck
• A52527             Self-Administered Drug Exclusion List and Biologicals Excluded from Coverage – Medical Policy Article (R7)
• A55426             Standard Documentation Requirements for All Claims Submitted to DME MACs
• L34540              Stretta Procedure
• L34087              Surveillance of Implantable or Wearable Cardioverter Defibrillators (ICDs): Office, Hospital, Web, or Non-Web Based
• L34084              Transcatheter Infusion Therapy
• A52415             Transcatheter Infusion Therapy – Supplemental Instructions Article
• L34337              Transesophageal Echocardiography (TEE)
• L36690              Wound Application of Cellular and/or Tissue Based Products (CTPs), Lower Extremities

Centers for Medicare & Medicaid Services (CMS) Local Coverage Determination (LCD) Updates »

Policy Alerts monitors Commercial and Medicare medical policies for changes. While medical Insurance carriers typically update medical policies annually, there are many reasons why they might review or update a policy. When reviews occur out of cycle they often go unnoticed. Policy Alerts keeps you updated when Payers make coverage changes to medical policies affecting your business.

Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on medical Insurance decisions in real-time. When changes occur, instant email alerts are delivered to your inbox. Clients have access to detailed coverage reports and medical policies through the interactive Policy Alerts Dashboard portal. Save time each month and keep focused on important Payer medical policy reviews and coverage decisions affecting your business!

Policy Alerts takes a client-focused hands-on approach and is constantly working to provide our customers with helpful insights and actionable analytics. We understand what our clients need and are dedicated to providing timely, accurate, and always up-to-date reports.

Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.